AIRLINK 80.20 Increased By ▲ 1.81 (2.31%)
BOP 5.30 Decreased By ▼ -0.04 (-0.75%)
CNERGY 4.39 Increased By ▲ 0.06 (1.39%)
DFML 33.19 Increased By ▲ 2.32 (7.52%)
DGKC 78.10 Decreased By ▼ -0.41 (-0.52%)
FCCL 20.47 Decreased By ▼ -0.11 (-0.53%)
FFBL 32.45 Increased By ▲ 0.15 (0.46%)
FFL 10.35 Increased By ▲ 0.13 (1.27%)
GGL 10.40 Increased By ▲ 0.11 (1.07%)
HBL 118.24 Decreased By ▼ -0.26 (-0.22%)
HUBC 135.30 Increased By ▲ 0.20 (0.15%)
HUMNL 6.83 Decreased By ▼ -0.04 (-0.58%)
KEL 4.61 Increased By ▲ 0.44 (10.55%)
KOSM 4.82 Increased By ▲ 0.09 (1.9%)
MLCF 38.40 Decreased By ▼ -0.27 (-0.7%)
OGDC 134.20 Decreased By ▼ -0.65 (-0.48%)
PAEL 23.80 Increased By ▲ 0.40 (1.71%)
PIAA 26.81 Increased By ▲ 0.17 (0.64%)
PIBTL 7.02 No Change ▼ 0.00 (0%)
PPL 113.40 Decreased By ▼ -0.05 (-0.04%)
PRL 28.11 Increased By ▲ 0.38 (1.37%)
PTC 14.89 Increased By ▲ 0.29 (1.99%)
SEARL 57.95 Increased By ▲ 1.45 (2.57%)
SNGP 67.40 Increased By ▲ 1.10 (1.66%)
SSGC 11.20 Increased By ▲ 0.26 (2.38%)
TELE 9.37 Increased By ▲ 0.22 (2.4%)
TPLP 11.75 Increased By ▲ 0.08 (0.69%)
TRG 73.20 Increased By ▲ 1.77 (2.48%)
UNITY 24.88 Increased By ▲ 0.37 (1.51%)
WTL 1.41 Increased By ▲ 0.08 (6.02%)
BR100 7,535 Increased By 42.5 (0.57%)
BR30 24,749 Increased By 190.7 (0.78%)
KSE100 72,396 Increased By 343.7 (0.48%)
KSE30 23,843 Increased By 35.3 (0.15%)

GENEVA: WHO experts warned Tuesday that repeating booster doses of the original Covid vaccines is not a viable strategy against emerging variants and called for new jabs that better protect against transmission.

An expert group created by the World Health Organization to assess the performance of Covid-19 vaccines said simply providing fresh jabs of existing Covid vaccines as new strains of the virus emerge was not the best way to fight the pandemic.

"A vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable," the WHO Technical Advisory Group on Covid-19 Vaccine Composition (TAG-Co-VAC) said in a statement.

It said preliminary data indicated the existing vaccines were less effective at preventing symptomatic Covid disease in people who have contracted the new Omicron variant, currently spreading like wildfire around the world.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

But protection against severe disease, which is what the jabs were especially intended to do, "is more likely to be preserved".

It recommended developing vaccines that not only protect people against falling seriously ill but could also better prevent infection and transmission in the first place.

"Covid-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed," TAG-Co-VAC said.

"Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current Covid-19 vaccines may need to be updated, to ensure that (they) continue to provide WHO-recommended levels of protection against infection and disease by VOCs (variants of concern), including Omicron and future variants."

Comments

Comments are closed.